Researchers of the CALIBER study compared the effectiveness of PPIs with laparoscopic magnetic sphincter augmentation among more than 150 patients with GERD with moderate-to-severe regurgitation.
Infection with HCV has been shown to be associated with an increased risk of cardiovascular disease events, but whether treatment with DAA agents affects this risk is currently unclear.
A new study presented during a late-breaking session at The Liver Meeting evaluated the safety and efficacy of oral seladelpar among more than 100 patients with primary biliary cholangitis.
Maintenance therapy with infliximab—an anti-tumor necrosis factor agent—is standard treatment for moderate to severe pediatric inflammatory bowel disease (IBD).
Patients with fecal incontinence (FI) and loose stool can decrease their likelihood of experiencing symptoms if they follow a diet low in fermentable oligo-, di-, and...
At ACG 2018, hepatologist Mitchell Shiffman, MD, outlined current concerns and special populations in the treatment of hepatitis C virus following the emergence of DAAs.
Researchers performed small RNA sequencing of colon tissue from more than 100 individuals to better understand cellular mechanisms that create heterogeneity in CD.
